Rare "crisis signal" triggers for third time in U.S. market

From Stansberry Research | Ad

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Click here for all the details.

ATYR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.70%

Insider Buying (Last 12 Months): $172,369.48

Insider Selling (Last 12 Months): $0.00

Atyr PHARMA Insider Trading History Chart

Atyr PHARMA Share Price & Price History

^$3.35

▲ +0.2 (6.35%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Atyr PHARMA Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/24/2024	Paul Schimmel	Director	Buy	52,300	$1.93	$100,939.00	413,023
7/22/2024	Paul Schimmel	Director	Buy	41,052	$1.74	$71,430.48	354,075

We recommended Palantir in 2021, now we’re recommending this...

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

SEC Filings (Institutional Ownership Changes) for Atyr PHARMA (NASDAQ:ATYR)

61.72% of Atyr PHARMA stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Read More

Today's Range

Now: $3.35

$3.13

$3.35

50 Day Range

MA: $3.17

$2.24

$3.56

52 Week Range

Now: $3.35

$1.28

$3.80

Volume

1,626,665 shs

Average Volume

600,098 shs

Market Capitalization

$281.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Who are the company insiders with the largest holdings of Atyr PHARMA?: Atyr PHARMA's top insider shareholders include:
Paul Schimmel (Director)
Learn More about top insider investors at Atyr PHARMA.

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.